Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Anti-Diabetes: An upshot - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 27, 2002

    Anti-Diabetes: An upshot

    Diabetes is one of the fastest growing epidemics globally. Statistics rolled out by World Health Organisation predicts that globally people suffering from this aliment would double to 300 m by 2025. Incidentally, India has one of the fastest growing diabetes patientís worldwide, thanks to rapid expansion of urbanization and consequent stress levels.

    Considering the data, there is an urgent need for research in this area. Let us understand what exactly the ailment is and how is therapeutic research moving in the insulin segment.

    Insulin is a hormone secreted by the pancreas and it is needed to metabolise sugar i.e. push glucose into the cells. When this process is upset it results in increased blood/ urine sugar. This condition is known as diabetes. Diabetes can be caused by inadequate insulin secretion (insulin sensitivity) or by the insulinís inability to metabolise sugar (insulin resistively).

    The domestic market size for anti-diabetes therapy is estimated to be over Rs 2 bn, growing over 30% yoy. Of the total anti-diabetes market, half the market is for insulin formulations with demand growing in the range of 25-30%. The balance of the market comprises of formulations of other anti-diabetic drugs.

    Dependent on the insulin shortfall in a personís body, there are two types of diabetes. Type I diabetes is a chronic condition when there is a severe lack of insulin in the body because auto-immune reactions have destroyed most or all of the insulin- secreting beta cells in the pancreas. Type I diabetes usually occurs in children and adults under the age of 30. However, Type I diabetes accounts for only 5-10% of the total market for anti-diabetes therapy.

    Type II diabetes is again a chronic condition that occurs when there is imbalance between the amount of insulin that can be produced by the beta cells and the bodyís need for insulin. The body may still be able to produce some insulin, though not enough for its needs, and / or the insulin produced in the body does not work properly due to insulin resistance. Type II diabetes is generally on account of genetic susceptibility and external / environmental factors.

    Over time beta cells in patients with Type II diabetes tend to produce decreasing quantities of insulin. Blood glucose control may be further compromised by increasing resistance to the actions of insulin, particularly in people who are overweight. In the first instance, the treatment aims at preserving or improving beta-cell function and insulin sensitivity. Globally, there is tremendous amount of research being conducted for improving insulin sensitivity. Let us further understand what does one mean by insulin sensitivity. Insulin resistance occurs when people with Type II diabetes produce large amounts of insulin, but their tissues do not respond appropriately to the action of the insulin. This often happens because the person is overweight and has fats and liver cells do not respond well to the insulin. Also, as people age, their cells lose some of their ability to respond to insulin in a psychological manner. Insulin resistance is often linked to high blood pressure and high levels of fat in the blood and several other disorders.

    Insulin sensitisers could offer a simple solution for various IRADís (Insulin resistance associated disorder). Different sensitisers offer solutions for different combinations of IRADís. Dr. Reddyís molecule, Ragaglitazar ĎDRF 2725í, which has been currently suspended from clinical trials by Novo Nordisk was a dual acting sensitiser for lowering blood glucose levels and putting a favorable effect on patientís lipid profile.

    Research in anti-diabetes area holds good potential. Globally, there is tremendous amount of research also being carried out on the delivery system for injecting insulin in the body. Oral insulin and insulin inhalers are two prominent areas.



    Equitymaster requests your view! Post a comment on "Anti-Diabetes: An upshot". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)